A Novel Inflammation-Based Stage (I Stage) in Patients with Resectable Esophageal Squamous Cell Carcinoma

Table 3

Univariate analyses for patients with ESCC.

	5-year CSS (%)	value	HR (95% CI)	value
Age (years)		0.978		0.978
≤60	30.1		1.000
>60	33.6		0.996 (0.762–1.302)
Gender		0.322		0.327
Female	38.1		1.000
Male	30.6		1.227 (0.815–1.848)
Tumor length (cm)		0.003		0.004
≤3	41.6		1.000
>3	27.8		1.580 (1.157–2.157)
Tumor location		0.556		0.564
Upper	41.2		1.000
Middle	33.1		0.735 (0.385–1.404)	0.351
Lower	29.0		0.908 (0.693–1.190)	0.483
Differentiation		0.198		0.207
Good	38.6		1.000
Moderate	31.0		1.185 (0.786–1.786)	0.417
Poor	28.6		1.504 (0.933–2.424)	0.098
Vessel involvement		0.007		0.008
Negative	34.1		1.000
Positive	18.9		1.577 (1.129–2.202)
Perineural invasion		0.005		0.006
Negative	35.0		1.000
Positive	17.5		1.551 (1.135–2.119)
TNM stage		<0.001		<0.001
I	51.9		1.000
II	32.7		1.878 (1.269–2.780)	0.002
III	18.8		2.943 (2.039–4.248)	<0.001
I stage		<0.001		<0.001
I0	50.0		1.000
I1	30.9		1.696 (1.189–2.420)	0.004
I2	18.2		2.676 (1.837–3.900)	<0.001
I3	8.3		4.372 (2.924–6.536)	<0.001
Adjuvant therapy		0.398		0.402
No	32.0		1.000
Yes	30.6		1.130 (0.849–1.504)
CRP (mg/L)		<0.001		<0.001
≤10.0	39.2		1.000
>10.0	17.1		2.217 (1.692–2.906)
NLR		<0.001		<0.001
≤3.5	39.0		1.000
>3.5	17.7		1.925 (1.471–2.519)
PLR		<0.001		<0.001
≤150	43.9		1.000
>150	17.3		2.260 (1.729–2.955)